AlphaOmega

Alpha Omega operates in the specialist neurotechnology market, with products serving both neuroscience research and clinical neurosurgery. Its portfolio includes Neuro Omega for microelectrode recording, research systems for neural recording and stimulation, electrode-positioning equipment, and αCare SENS™ for care around DBS therapy. This mix differentiates its described offering from larger medical-device companies such as Medtronic, Abbott, and Boston Scientific, which have broad neuromodulation and DBS portfolios: Alpha Omega’s product descriptions also emphasize research instrumentation and clinical neurophysiology workflows. Those companies are useful market context, not confirmed direct matches for every product or customer segment. Its stated focus on combining hardware and software for recording, mapping, navigation, and care coordination suggests a specialist position across research and clinical workflows.

Alpha Omega’s trajectory reflects a long operating history and a specialized product portfolio, rather than a clearly documented sequence of recent financing or expansion milestones. Founded in 1993, the company has developed products spanning clinical microelectrode recording, neural research, electrode positioning, and DBS-related care. The clearest financial inflection point in the available company profile is a $7 million Venture Round announced on Dec 11, 2018, with GIBF as lead investor; no later funding round is listed. The company’s employee range is estimated at 101–250, but there is no comparable historical headcount series to quantify hiring or growth. As a result, the evidence supports continued activity and a broadening product set, but not a quantified growth rate. Further assessment would require dated product releases, revenue or deployment indicators, and updated employee figures.